Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in a deal that brings an in vivo cell-therapy platform into BMS’s immunology pipeline. Orbital’s technology delivers CAR constructs directly in vivo, aiming to simplify manufacturing and broaden patient access compared with autologous CAR‑T. The move places BMS alongside peers buying in vivo cell therapy assets to accelerate clinical programs and platform capabilities. Analysts see the acquisition as a strategic shortcut to an emerging modality that could reduce cost and scale barriers for autoimmune and other indications.